2292. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH1, Kim TY2, Kim GM3, Kang SY4, Park IH5, Kim JH6, Lee KE7, Ahn HK8, Lee MH9, Kim HJ10, Kim HJ11, Lee JI12, Koh SJ13, Kim JY14, Lee KH2, Sohn J3, Kim SB15, Ahn JS14, Im YH14, Jung KH15, Im SA2; Korean Cancer Study Group (KCSG).
Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24.
Link